Open Access

MiR‑1260b inhibitor enhances the chemosensitivity of colorectal cancer cells to fluorouracil by targeting PDCD4/IGF1

  • Authors:
    • Jun Zhao
    • Jingjie Cao
    • Lurong Zhou
    • Yunyi Du
    • Xiaoling Zhang
    • Bo Yang
    • Yangjun Gao
    • Yu Wang
    • Ning Ma
    • Wei Yang
  • View Affiliations

  • Published online on: August 14, 2018     https://doi.org/10.3892/ol.2018.9307
  • Pages: 5131-5139
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is the most common malignant tumor type and has become resistant to 5‑fluorouracil (5‑FU) in recent decades, which is one of the most popular therapies. Recently, microRNA (miRNA or miR) has been investigated as a potential therapeutic strategy for CRC. However, there has been little investigation of the underlying mechanism of the association between expression of miRNA and chemosensitivity. The present study aimed to investigate the effect of miR‑1260b inhibitor on CRC cells, and their chemosensitivity to 5‑FU, by treating them with the miR‑1260b inhibitor. miR‑1260b inhibitor was demonstrated to significantly promote the proliferation and invasion of the CRC cell line, HCT116, and to increase the apoptotic rate. Furthermore, it was validated that programmed cell death 4 (PDCD4) was a direct target of miR‑1260b inhibitor in CRC with bioinformatics tools and a luciferase assay. Western blot analysis revealed that miR‑1260b inhibitor could significantly decrease PDCD4 expression, and downregulate the expression of phosphorylated‑Akt (p‑Akt) and phosphorylated‑extracellular‑signal‑regulated kinase (p‑ERK). In conclusion, it was confirmed that the anti‑tumor effect of the miR‑1260b inhibitor was conducted by blocking the phosphorylated 3‑kinase/Akt pathway as dysregulated protein expression induced by miR‑1260b inhibitor was rescued by insulin‑like growth factor. Notably, miR‑1260b inhibitor could significantly enhanced the chemoresponse of HCT116 cells to 5‑FU via reduced proliferation, increased apoptosis, and downregulation of PDCD4, p‑Akt and p‑ERK protein expression. In summary, the present study may provide a novel direction for future clinical therapy to enhance the chemosensitivity of tumor cells.

References

1 

Kraus S, Nabiochtchikov I, Shapira S and Arber N: Recent advances in personalized colorectal cancer research. Cancer Lett. 347:15–21. 2014. View Article : Google Scholar : PubMed/NCBI

2 

O Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer 6th edition staging. J Natl Cancer Inst. 96:1420–1425. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Ferlay J, Shin HR, Bray F, Forman D, Mather C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Nagtegaal ID, Quirke P and Schmoll HJ: Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol. 9:119–123. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Watanabe T: Biomarker for high-risk patients with stage II colon cancer. Lancet Oncol. 14:1247–1248. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Chua YJ and Zalcberg JR: Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther. 8:595–604. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Grady WM and Pritchard CC: Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 42:124–139. View Article : Google Scholar : PubMed/NCBI

8 

Ye JJ and Cao J: MicroRNAs in colorectal cancer as markers and targets: Recent advances. World J Gastroenterol. 20:4288–4299. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Ma J, Dong C and Ji C: MicroRNA and drug resistance. Cancer Gene Ther. 17:523–531. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Oqin S, Chan AT, Fuchs CS and Giovannucci E: Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut. 60:397–411. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Luo Y, Tsuchiya KD, ll Park D, Fausel R, Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J and Grady WM: RET is a potential tumor suppressor gene in colorectal cancer. Oncogene. 32:2037–2047. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Wiemer EA: The role of microRNAs in cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Hernando E: microRNAs and cancer: Role in tumorigenesis, patient classification and therapy. Clin Transl Oncol. 9:155–160. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Boil Chem. 285:17442–17452. 2010. View Article : Google Scholar

16 

Zhou JJ, Zheng S, Sun LF and Zheng L: MicroRNA regulation network in colorectal cancer metastasis. World J Biol Chem. 5:301–307. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Vilarr E, Tabernero J and Gruber SB: Micromanaging the classification of colon cancer: The role of the microRNAome. Clin Cancer Res. 17:7207–7209. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Cummins JM, He Y, Leary RJ, Paqliarini R, Diaz LA Jr, Sjiblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, et al: The colorectal microRNAome. Proc Natl Acad Sci USA. 103:3687–3692. 2006. View Article : Google Scholar : PubMed/NCBI

19 

Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs protential utility in colon cancer: Early detection, prognosis and chemosensitivity. World J Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Di Leva G, Cheung DG and Croce CM: miRNA clusters as therapeutic targets for hormone-resistant. Expert Rev Endocrinol Metab. 10:607–617. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Liu DR, Guan QL, Limin X, Gao MT, Jiang L and Kang HX: MiR-1260b is a potential prognostic biomarker in colorectal cancer. Med Sci Monit. 22:2417–2423. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Hirata H, Ueno K, Nakajima K, Tabatatai ZL, Hinoda Y, Ishii N and Dahiya R: Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer. 108:2070–2078. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Afonia O, Juste D, Das S, Matsuhashi S and Samuels HH: Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antagonist in breast cancer cells. Oncogene. 23:8135–8145. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Jansen AP, Camalier CE, Stark C and Colburn NH: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 3:103–110. 2004.PubMed/NCBI

25 

Wei N, Liu SS, Chan KK and Ngan HY: Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 7:e303112012. View Article : Google Scholar : PubMed/NCBI

26 

Yin K, Liu MH, Zhang M, Wang F, Fen M, Liu ZJ, Yuan Y, Gao S, Yang L, Zhang W, et al: miR-208a-3p suppresses cell apoptosis by targeting PDCD4 in gastric cancer. Oncotarget. 7:67321–67332. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Shen F, Mo M, Chen L, An S, Tan X, Fu Y, Rezaei K, Wang Z, Zhang L and Fu SW: MicroRNA-21 down-regulates Rb1 expression by targeting PDCD4 in retinoblastoma. J Cancer. 5:804–812. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M and Stallings RL: MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer. 9:832010. View Article : Google Scholar : PubMed/NCBI

29 

Gao N, Budhraja A, Cheng S, Liu EH, Chen J, Yang Z, Chen D, Zhang Z and Shi X: Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways. Cell Death Dis. 2:e1402011. View Article : Google Scholar : PubMed/NCBI

30 

Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E, Marincola FM, Mai C, Chen Y and Wei H: Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 4:e6342013. View Article : Google Scholar : PubMed/NCBI

31 

Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, Yang SM, Wang RQ and Fang DC: Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol Diagn Ther. 14:155–161. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Ivanov VN, Krasilnikov M and Ronai Z: Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 277:4932–4944. 2002. View Article : Google Scholar : PubMed/NCBI

33 

Justus CR, Leffler N, Ruiz-Echevarria M and Yang LV: In vitro cell migration and invasion assay. J Vis Exp. 1–Jun;2014. View Article : Google Scholar : PubMed/NCBI

34 

Livak KJ and Schmitten TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2011. View Article : Google Scholar

35 

Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo OE, Seckl M and Holcik M: Tumor suppressor PDCD4 repressed internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Mol Cell Biol. 32:1818–1829. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Zhang S, Li J, Jiang Y, Xu Y and Oin C: Programmed cell death 4 (Pdcd4) suppresses metastatic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 28:712009. View Article : Google Scholar : PubMed/NCBI

37 

Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Navarro-Quiroz E, Pacheco-Lugo L, Navarro-Quiroz R, Lorenzi H, España-Puccini P, Díaz-Olmos Y, Almendrales L, Olave V, Gonzalez-Torres H, Diaz-Perez A, et al: Profiling analysis of circulating microRNA in peripheral blood of patients with class IV lupus nephritis. PLoS One. 12:e01879732017. View Article : Google Scholar : PubMed/NCBI

39 

Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL and Dahiya R: Genistein down regulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer. 110:1645–1654. 2014. View Article : Google Scholar : PubMed/NCBI

40 

Xu L, Li L, Li J, Li H, Shen Q, Ping J, Ma Z, Zhong J and Dai L: Overexpression of miR-1260b in non-samll cell lung cancer is associated with lymph node metastasis. Aging Dis. 6:478–485. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Nordentoft I, Birkenkamp-Demtroder K, Agerbak M, Thedorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 5:402012. View Article : Google Scholar : PubMed/NCBI

42 

Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al: MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA. 107:20198–21103. 2010. View Article : Google Scholar

43 

Zhang Z and DuBois RN: Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene. 20:4450–4456. 2001. View Article : Google Scholar : PubMed/NCBI

44 

Palamarchuk K, Efanov A, Maximov V, Aqeilan RI and Croce CMP: Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 65:11282–11286. 2005. View Article : Google Scholar : PubMed/NCBI

45 

Bitomsky N, Bohm M and Klempnauer KH: Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 23:7484–7493. 2004. View Article : Google Scholar : PubMed/NCBI

46 

Lankat-Buttgereit B, Muller S, Schmidt H, Parhofer KG, Gress TM and Göke R: Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Bio Cell. 100:703–715. 2008. View Article : Google Scholar

47 

Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH and Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition, correlates inversely with pAkt and is a new and independent prognostic factor in resected colorectal cancer. Cancer. 110:1697–1707. 2007. View Article : Google Scholar : PubMed/NCBI

48 

Otaegi G, Yusta-Boyo MJ, Vergaño-Vera E, Méndez-Gómez HR, Carrera AC, Abad JL, González M, de la Rosa EJ, Vicario-Abejón C and de Pablo F: Modulation of the PI 3-kinase-Akt signalling pathway by IGF-I and PTEN regulates the differentiation of neural stem/precursor cells. J Cell Sci. 119:2739–2748. 2006. View Article : Google Scholar : PubMed/NCBI

49 

Cui QL and Almazan G: IGF-1 induced oligodendrocyte progenitor proliferation requires PI3K/Akt, MEK/ERK and Src-like tyrosine kinases. J Neurochemistry. 217:361–370. 2009.

Related Articles

Journal Cover

October 2018
Volume 16 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhao, J., Cao, J., Zhou, L., Du, Y., Zhang, X., Yang, B. ... Yang, W. (2018). MiR‑1260b inhibitor enhances the chemosensitivity of colorectal cancer cells to fluorouracil by targeting PDCD4/IGF1. Oncology Letters, 16, 5131-5139. https://doi.org/10.3892/ol.2018.9307
MLA
Zhao, J., Cao, J., Zhou, L., Du, Y., Zhang, X., Yang, B., Gao, Y., Wang, Y., Ma, N., Yang, W."MiR‑1260b inhibitor enhances the chemosensitivity of colorectal cancer cells to fluorouracil by targeting PDCD4/IGF1". Oncology Letters 16.4 (2018): 5131-5139.
Chicago
Zhao, J., Cao, J., Zhou, L., Du, Y., Zhang, X., Yang, B., Gao, Y., Wang, Y., Ma, N., Yang, W."MiR‑1260b inhibitor enhances the chemosensitivity of colorectal cancer cells to fluorouracil by targeting PDCD4/IGF1". Oncology Letters 16, no. 4 (2018): 5131-5139. https://doi.org/10.3892/ol.2018.9307